AASLD 2018 Late-breaking posters
LB-13:
Safety, Pharmacokinetics and Anti-Viral
Efficacy of Novel Core Protein Allosteric Modifier GLS4
in Patients with Chronic Hepatitis B: Interim Results
from a 48 Weeks Phase 2a Study
LB-14:
A Nasal Administrative Therapeutic Vaccine
(NASVAC) with Modified Treatment Strategy Reduces
and Eliminates Hbs Antigen in HBV Infected Patients
with or without Nucleos(t)Ide Analogs Therapy
LB-25:
First Results with RNA Interference (RNAi) in
Chronic Hepatitis B (CHB) Using ARO-HBV
LB-33:
TLR7 Agonist RO7020531 Triggers Immune
Activation after Multiple Doses in Chronic Hepatitis B
Patients
AASLD 2018最新海报
LB-13:
安全性,药代动力学和抗病毒
新型核心蛋白质变构修饰剂GLS4的功效
在慢性乙型肝炎患者中:中期结果
来自48周的2a期研究
LB-14:
鼻腔行政治疗性疫苗
(NASVAC)改进治疗策略减少
并消除HBV感染患者的Hbs抗原
有或没有Nucleos(t)Ide类似物治疗
LB-25:
RNA干扰(RNAi)的第一个结果
慢性乙型肝炎(CHB)使用ARO-HBV
LB-33:
TLR7激动剂RO7020531触发免疫
多次服用慢性乙型肝炎后的激活
患者作者: newchinabok 时间: 2018-10-20 22:10